These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36482193)

  • 1. Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10.
    Kristeleit RS; Drew Y; Oza AM; Domchek SM; Banerjee S; Glasspool RM; Balmaña J; Chen LM; Patel MR; Burris HA; Safra T; Borrow J; Lin KK; Goble S; Maloney L; Shapira-Frommer R
    Br J Cancer; 2023 Jan; 128(2):255-265. PubMed ID: 36482193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
    Swisher EM; Lin KK; Oza AM; Scott CL; Giordano H; Sun J; Konecny GE; Coleman RL; Tinker AV; O'Malley DM; Kristeleit RS; Ma L; Bell-McGuinn KM; Brenton JD; Cragun JM; Oaknin A; Ray-Coquard I; Harrell MI; Mann E; Kaufmann SH; Floquet A; Leary A; Harding TC; Goble S; Maloney L; Isaacson J; Allen AR; Rolfe L; Yelensky R; Raponi M; McNeish IA
    Lancet Oncol; 2017 Jan; 18(1):75-87. PubMed ID: 27908594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed,
    Kristeleit RS; Oaknin A; Ray-Coquard I; Leary A; Balmaña J; Drew Y; Oza AM; Shapira-Frommer R; Domchek SM; Cameron T; Maloney L; Goble S; Lorusso D; Ledermann JA; McNeish IA
    Int J Gynecol Cancer; 2019 Nov; 29(9):1396-1404. PubMed ID: 31685558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
    Oza AM; Tinker AV; Oaknin A; Shapira-Frommer R; McNeish IA; Swisher EM; Ray-Coquard I; Bell-McGuinn K; Coleman RL; O'Malley DM; Leary A; Chen LM; Provencher D; Ma L; Brenton JD; Konecny GE; Castro CM; Giordano H; Maloney L; Goble S; Lin KK; Sun J; Raponi M; Rolfe L; Kristeleit RS
    Gynecol Oncol; 2017 Nov; 147(2):267-275. PubMed ID: 28882436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline
    Kristeleit R; Shapiro GI; Burris HA; Oza AM; LoRusso P; Patel MR; Domchek SM; Balmaña J; Drew Y; Chen LM; Safra T; Montes A; Giordano H; Maloney L; Goble S; Isaacson J; Xiao J; Borrow J; Rolfe L; Shapira-Frommer R
    Clin Cancer Res; 2017 Aug; 23(15):4095-4106. PubMed ID: 28264872
    [No Abstract]   [Full Text] [Related]  

  • 6. Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.
    Kristeleit R; Lisyanskaya A; Fedenko A; Dvorkin M; de Melo AC; Shparyk Y; Rakhmatullina I; Bondarenko I; Colombo N; Svintsitskiy V; Biela L; Nechaeva M; Lorusso D; Scambia G; Cibula D; Póka R; Oaknin A; Safra T; Mackowiak-Matejczyk B; Ma L; Thomas D; Lin KK; McLachlan K; Goble S; Oza AM
    Lancet Oncol; 2022 Apr; 23(4):465-478. PubMed ID: 35298906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Coleman RL; Oza AM; Lorusso D; Aghajanian C; Oaknin A; Dean A; Colombo N; Weberpals JI; Clamp A; Scambia G; Leary A; Holloway RW; Gancedo MA; Fong PC; Goh JC; O'Malley DM; Armstrong DK; Garcia-Donas J; Swisher EM; Floquet A; Konecny GE; McNeish IA; Scott CL; Cameron T; Maloney L; Isaacson J; Goble S; Grace C; Harding TC; Raponi M; Sun J; Lin KK; Giordano H; Ledermann JA;
    Lancet; 2017 Oct; 390(10106):1949-1961. PubMed ID: 28916367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline
    Poveda AM; Davidson R; Blakeley C; Milner A
    Future Oncol; 2019 Nov; 15(32):3651-3663. PubMed ID: 31553234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
    Moore KN; Secord AA; Geller MA; Miller DS; Cloven N; Fleming GF; Wahner Hendrickson AE; Azodi M; DiSilvestro P; Oza AM; Cristea M; Berek JS; Chan JK; Rimel BJ; Matei DE; Li Y; Sun K; Luptakova K; Matulonis UA; Monk BJ
    Lancet Oncol; 2019 May; 20(5):636-648. PubMed ID: 30948273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
    Ledermann JA; Oza AM; Lorusso D; Aghajanian C; Oaknin A; Dean A; Colombo N; Weberpals JI; Clamp AR; Scambia G; Leary A; Holloway RW; Gancedo MA; Fong PC; Goh JC; O'Malley DM; Armstrong DK; Banerjee S; García-Donas J; Swisher EM; Cameron T; Maloney L; Goble S; Coleman RL
    Lancet Oncol; 2020 May; 21(5):710-722. PubMed ID: 32359490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer.
    Monk BJ; Coleman RL; Fujiwara K; Wilson MK; Oza AM; Oaknin A; O'Malley DM; Lorusso D; Westin SN; Safra T; Herzog TJ; Marmé F; N Eskander R; Lin KK; Shih D; Goble S; Grechko N; Hume S; Maloney L; McNeish IA; Kristeleit RS
    Int J Gynecol Cancer; 2021 Dec; 31(12):1589-1594. PubMed ID: 34593565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse.
    Ma Y; Liu J; Li N; Bu H; Huang Y; Jin C; Wen H; Feng S; Zhang H; Yang X; Kong B; Wu L; Song K
    J Ovarian Res; 2023 Oct; 16(1):209. PubMed ID: 37891662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis.
    Poveda A; Lheureux S; Colombo N; Cibula D; Lindemann K; Weberpals J; Bjurberg M; Oaknin A; Sikorska M; González-Martín A; Madry R; Pérez MJR; Ledermann J; Davidson R; Blakeley C; Bennett J; Barnicle A; Škof E
    Gynecol Oncol; 2022 Mar; 164(3):498-504. PubMed ID: 35063276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
    Drew Y; Ledermann J; Hall G; Rea D; Glasspool R; Highley M; Jayson G; Sludden J; Murray J; Jamieson D; Halford S; Acton G; Backholer Z; Mangano R; Boddy A; Curtin N; Plummer R
    Br J Cancer; 2016 Mar; 114(7):723-30. PubMed ID: 27002934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rucaparib: a novel PARP inhibitor for
    Colombo I; Lheureux S; Oza AM
    Drug Des Devel Ther; 2018; 12():605-617. PubMed ID: 29606854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
    Swisher EM; Kristeleit RS; Oza AM; Tinker AV; Ray-Coquard I; Oaknin A; Coleman RL; Burris HA; Aghajanian C; O'Malley DM; Leary A; Welch S; Provencher D; Shapiro GI; Chen LM; Shapira-Frommer R; Kaufmann SH; Goble S; Maloney L; Kwan T; Lin KK; McNeish IA
    Gynecol Oncol; 2021 Dec; 163(3):490-497. PubMed ID: 34602290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain - A GEICO study.
    Yubero A; Barquín A; Estévez P; Pajares B; Sánchez L; Reche P; Alarcón J; Calzas J; Gaba L; Fuentes J; Santaballa A; Salvador C; Manso L; Herrero A; Taus Á; Márquez R; Madani J; Merino M; Marquina G; Casado V; Constenla M; Gutiérrez M; Dosil A; González-Martín A
    BMC Cancer; 2022 Nov; 22(1):1150. PubMed ID: 36348385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma.
    Oza AM; Lorusso D; Aghajanian C; Oaknin A; Dean A; Colombo N; Weberpals JI; Clamp AR; Scambia G; Leary A; Holloway RW; Gancedo MA; Fong PC; Goh JC; O'Malley DM; Armstrong DK; Banerjee S; García-Donas J; Swisher EM; Cella D; Meunier J; Goble S; Cameron T; Maloney L; Mörk AC; Bedel J; Ledermann JA; Coleman RL
    J Clin Oncol; 2020 Oct; 38(30):3494-3505. PubMed ID: 32840418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.
    Konecny GE; Oza AM; Tinker AV; Oaknin A; Shapira-Frommer R; Ray-Coquard I; Aghajanian C; Coleman RL; O'Malley DM; Leary A; Chen LM; Provencher D; Ma L; Brenton JD; Castro C; Green M; Simmons AD; Beltman J; Harding T; Lin KK; Goble S; Maloney L; Kristeleit RS; McNeish IA; Swisher EM; Xiao JJ
    Gynecol Oncol; 2021 Jun; 161(3):668-675. PubMed ID: 33752918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial.
    Lee JM; Moore RG; Ghamande S; Park MS; Diaz JP; Chapman J; Kendrick J; Slomovitz BM; Tewari KS; Lowe ES; Milenkova T; Kumar S; Dymond M; Brown J; Liu JF
    Clin Cancer Res; 2022 Oct; 28(19):4186-4193. PubMed ID: 35917514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.